Facebook
X
LinkedIn
ForwardRobert Svatek, MD
Dr. Svatek’s is a recognized nationally as an expert in the management of superficial and advanced bladder cancer and is a recognized high-volume bladder cancer surgeon, performing total intracorporeal urinary diversions. He provides state-of-the-art surgical options, including robotic-assisted and open approaches, as well as all available urinary diversion options, including ileal conduit and continent diversions (Indiana pouch and neobladder).
In addition to his work in the clinical arena, Dr. Robert Svatek is a surgeon-scientist with clinical expertise in early and late-phase clinical trials and urologic cancers. His laboratory expertise is in cancer immunology with an emphasis on understanding the immunopathologic basis of urothelial carcinoma and development of novel immunotherapeutic agents. Research conducted in his lab is rapidly translated into novel clinical trials. Current projects include chemokine signaling mechanisms driving bladder cancer growth and response to immunotherapy, role of innate immune cells including natural killer cells and gamma delta T cells in tumor immunology, significance of regulatory T cells in bladder cancer pathology, and mechanisms underlying BCG immunotherapy.
In addition to his work in the clinical arena, Dr. Robert Svatek is a surgeon-scientist with clinical expertise in early and late-phase clinical trials and urologic cancers. His laboratory expertise is in cancer immunology with an emphasis on understanding the immunopathologic basis of urothelial carcinoma and development of novel immunotherapeutic agents. Research conducted in his lab is rapidly translated into novel clinical trials. Current projects include chemokine signaling mechanisms driving bladder cancer growth and response to immunotherapy, role of innate immune cells including natural killer cells and gamma delta T cells in tumor immunology, significance of regulatory T cells in bladder cancer pathology, and mechanisms underlying BCG immunotherapy.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Ferring PharmaceuticalsDate added:Date updated:04/04/2025